UA-45667900-1
Showing posts with label Fragile X. Show all posts
Showing posts with label Fragile X. Show all posts

Thursday, 5 November 2026

Recent Advances in Therapies for Potassium Ion Channel Dysfunction in Autism

 

Ο ήλιος, η θάλασσα και το EpiphanyASD — οι καλύτερες συνθήκες για να ανοίξουν νέα κανάλια σκέψης!


A recent comment from Konstantinos prompted this update to my earlier posts on potassium channels. Progress is being made, particularly in Fragile X, but also potentially for a sub-group of idiopathic autism with a specific pattern in their EEG.

  

From the original channelASD hypothesis to drugs entering clinical trials

Back in 2015, I wrote about the possibility of classifying some forms of autism according to dysfunction in particular ion channels. I used the term channelASD, drawing attention to potassium (Kv), sodium (Nav) and calcium (Cav) channels.

At the time, this was largely a mechanism-driven hypothesis. We knew that ion channels regulate neuronal excitability, and genetic research was beginning to implicate ion-channel genes in neurodevelopmental disorders. The therapeutic question was whether correcting a specific channel abnormality might improve some of the symptoms associated with autism.

More than a decade later, there are some interesting developments.

Two different potassium-channel activators are now attracting attention. Azetukalner, a Kv7 potassium-channel opener developed by Xenon Pharmaceuticals, has reached late-stage clinical development for epilepsy, with a New Drug Application submitted to the FDA in September 2026. Meanwhile, Spinogenix has announced a new autism study of codabakalner (SPG601), which activates a different potassium-channel family, BK channels. A second BK-channel opener, KER-0193, is also heading into Phase 2 in Fragile X syndrome.

None of these drugs has been demonstrated yet to treat autism. Nevertheless, these developments suggest that the ion-channel hypothesis deserves another look.

 

1. Why potassium channels matter

Potassium channels help control the electrical activity of neurons. When a neuron becomes activated, the movement of potassium ions across its membrane helps regulate the duration of electrical signals and determines how readily the neuron can fire again.

Different potassium channels operate at different stages of neuronal activity.

•        Kv7 channels help stabilise the resting membrane potential and limit repetitive neuronal firing. Kv7 plays a role in sensory gating, which is very often disturbed in autism.

•        BK channels are activated by both intracellular calcium and membrane depolarisation, helping regulate action potentials and neurotransmitter release. BK channels may help regulate sensory filtering and habituation.

•        SK channels are activated by intracellular calcium and contribute to after-hyperpolarisation, influencing how frequently neurons fire. SK channels help regulate neuronal firing patterns and sensory-signal processing, making them plausible contributors to sensory-processing abnormalities in autism; however, their role is complex, and the evidence for a specific SK-channel mechanism in autism remains limited.

•        Kv3 channels help certain neurons fire at high frequencies with precise timing, which is important for synchronised neural activity. Kv3 channels are a promising target for investigating sensory hypersensitivity in autism

•        Slack (KNa) channels are sodium-activated potassium channels that are directly regulated by FMRP, the protein missing in Fragile X syndrome.

It is tempting to think of potassium-channel activation as a general way to calm an overactive brain. However, this is too simple. Different channels have different functions, and some forms of neurodevelopmental disorder involve channels that are overactive rather than underactive.

The therapeutic objective should therefore be to correct the relevant physiological abnormality, not simply to increase potassium-channel activity.

A useful review is Potassium channels and autism spectrum disorder: An overview (2021), which discusses several potassium-channel genes implicated in neurodevelopmental disorders.

Read the review

2. Azetukalner: Kv7 channel activation reaches the FDA

Our very active reader, Konstantinos, recently commented on my old channelASD article:

"Ancient post, but Xenon filed for FDA approval of azetukalner, a potassium channel opener. Epiphany is such a precious knowledge place :)"

Thank you, Konstantinos!

Azetukalner is a Kv7 channel opener developed by Xenon Pharmaceuticals. Positive Phase 3 results (X-TOLE2) in focal-onset seizures were announced in March 2026, and on 17 September 2026 the company announced submission of a New Drug Application to the FDA.

Kv7.2 and Kv7.3 channels, encoded by KCNQ2 and KCNQ3, contribute to the neuronal M-current. This current acts as an important brake on repetitive firing.

Enhancing Kv7 activity can reduce neuronal excitability, which is why this channel family has attracted considerable interest in epilepsy drug development.

The progress of azetukalner demonstrates that Kv7 modulation can be translated into a clinically advanced treatment strategy.

Xenon is running Phase 3 studies of azetukalner in major depressive disorder (X-NOVA2 and X-NOVA3) and in bipolar depression, with topline data from X-NOVA2 expected in the first half of 2027. Those trials will tell us a good deal about how a Kv7 opener behaves in a psychiatric population, including its tolerability, although they say nothing directly about autism.

Xenon's September 2026 announcement

 

An important complication: some KCNQ mutations increase channel activity

Genetic studies have identified individuals with KCNQ2 or KCNQ3 gain-of-function variants who have developmental delay, language impairment and autistic features.

Sands et al. (2019) described 11 people with KCNQ3 gain-of-function variants. All had developmental delay and autistic features, while five received a formal autism diagnosis.

A separate study of 15 individuals with KCNQ2 gain-of-function variants found autistic features in ten.

These findings are particularly interesting because they challenge the idea that opening potassium channels should always be beneficial. In these particular genetic disorders, the channel is already excessively active. Further activation might be counterproductive.

The clinical implications are not straightforward, because the relationship between channel activity and neuronal network function is complex. Nevertheless, these studies illustrate why a genetic diagnosis and, where possible, functional characterisation may be important when considering targeted treatment.

3. BK channels: from Fragile X mouse studies to a human autism trial

Another strand of my earlier writing concerned calcium-activated potassium channels, particularly BK and SK channels.

The BK channel, encoded by KCNMA1, is activated by intracellular calcium and membrane depolarisation. It contributes to the regulation of neuronal firing and synaptic function.

Fragile X syndrome is particularly relevant to this line of research because loss of FMRP affects the regulation of numerous synaptic proteins and ion channels.

Human genetic evidence for BK channels

The case for BK channels does not rest only on mouse models. In 2006, Laumonnier and colleagues reported a person with autism and intellectual disability in whom the KCNMA1 gene was physically disrupted by a chromosomal translocation. The gene showed haploinsufficiency and the resulting BK channel activity was reduced, but could be enhanced in vitro by a BK-channel opener.

This is a single case, and a loss of BK function in one individual is not the same as a shared defect in Fragile X. It does, however, give the BK hypothesis a human genetic foothold.

Laumonnier et al., 2006, American Journal of Psychiatry

FRAXA published a helpful overview of the BK story in April 2026.

FRAXA: Opening the Gate — BK channel modulation in Fragile X

 

Chlorzoxazone

In 2024, Ferraguto and colleagues published a study of chlorzoxazone in a mouse model of Fragile X syndrome.

Chlorzoxazone is an existing muscle relaxant that can activate BK channels, although it is not a selective BK-channel drug.

In the Fmr1-knockout mouse model, chlorzoxazone improved several experimental outcomes, including hyperactivity, acoustic hyper-responsiveness and social-interaction measures. The investigators also reported restoration of impaired BK currents in hippocampal and cortical neurons.

The study provides preclinical evidence supporting BK channels as a potential therapeutic target in Fragile X syndrome.

This research is particularly relevant to the problem of sound sensitivity. In some individuals with autism, sound hypersensitivity can be severely disabling. Fragile X mouse models provide a way to investigate the underlying auditory physiology and test candidate treatments.

However, sound hypersensitivity can arise from several mechanisms, including abnormalities in peripheral auditory processing as well as central neural circuits. A drug that helps one mechanism may not help another.

 

Codabakalner (SPG601)

The most important recent development is the progression of BK-channel activation into human clinical research.

In April 2026, Pedapati and colleagues published a randomised, double-blind, placebo-controlled crossover study of SPG601 in ten adult men with genetically confirmed Fragile X syndrome.

Following a single 800 mg dose, the investigators reported changes in resting-state EEG gamma power and other EEG measures, alongside improvement on a measure of attention and inhibitory control.

Not every measure improved: auditory-evoked gamma outcomes did not show significant treatment effects.

The study was small and examined a single dose, so it cannot establish long-term efficacy. Nevertheless, it provides initial human evidence that BK-channel activation can produce measurable neurophysiological effects.

Read the original study in Scientific Reports


The new autism study

In October 2026, Spinogenix announced that it was adding a Phase IIb study of codabakalner to its CLARITY programme, specifically targeting idiopathic autism.

CLARITY is a Phase 2b/3 basket trial (NCT07439510). The Fragile X part enrols men with full-mutation Fragile X syndrome, and the autism part is a Phase 2b study in adults. According to the ClinicalTrials.gov record, the trial was listed as not yet recruiting in October 2026, with an estimated start date of December 2026 and an estimated primary completion date of February 2030. Codabakalner has FDA Fast Track designation for Fragile X syndrome, and CLARITY has grant support from the FRAXA Research Foundation. Readers should therefore not expect results for several years.

The proposed recruitment strategy is particularly interesting. Participants will be screened using EEG, with enrolment focused on individuals who have elevated resting gamma-band power resembling a pattern observed in Fragile X syndrome.

In the reported EEG analysis, this signature was found in 35 of 159 autistic participants, or approximately 22%. Among adults, the proportion was 23 of 72, or approximately 32%.

The subgroup could not be reliably distinguished from other autistic participants using 27 conventional clinical assessments after statistical correction.

The investigators therefore propose that EEG may identify a biologically relevant subgroup that would otherwise be missed by behavioural assessment alone.

This is an important hypothesis, but it remains to be validated. An EEG pattern resembling that of Fragile X syndrome does not prove that the same molecular defect is present, nor does it establish that an individual will respond to a BK-channel activator.

The decisive question is whether participants selected by this EEG signature experience meaningful clinical improvement compared with placebo.

ClinicalTrials.gov record for CLARITY (NCT07439510)

Spinogenix announcement of the autism Phase 2b study

 

A second BK opener: KER-0193

Codabakalner is no longer the only BK-channel modulator in clinical development. In September 2025, Servier agreed to acquire KER-0193 from Kaerus Bioscience in a deal worth up to $450 million. KER-0193 is an oral small-molecule BK-channel modulator being developed for Fragile X syndrome.

A Phase 1 study in 56 healthy volunteers found it safe and well tolerated, and an EEG substudy was reported to show proof of mechanism. The FDA has granted it orphan drug and rare paediatric drug designations for Fragile X syndrome, and Servier planned to start a Phase 2 trial in Fragile X patients in 2026.

The significance here is that two independent companies are now testing BK-channel modulators in humans. That does not make either drug effective, but it makes the target harder to dismiss. As with codabakalner, the indication is Fragile X syndrome, not autism in general.

Servier's acquisition of KER-0193

 

4. My earlier interest in mefenamic acid (Ponstan)

Another old EpiphanyASD research thread concerned mefenamic acid, marketed as Ponstan, and its possible effects on potassium channels.

Ponstan is widely used as a pain medication in many countries. In Greece it is OTC and very cheap - there is even a liquid version for children. It is very common in India. In the US it is 10 to 100 times more expensive, so buyer beware.

In my 2016 post, I discussed research showing that related fenamate compounds, including meclofenamic acid and diclofenac, can activate Kv7.2/Kv7.3 currents in experimental systems.

This was an intriguing connection because the neuronal M-current is a well-established regulator of excitability.

In a later post, I explored mefenamic acid's multiple biological effects and its possible relevance to sound sensitivity in Monty. This was an individual observation and a mechanistic hypothesis, not evidence from a controlled autism trial.

My 2016 post on mefenamic acid and autism

My later post on fenamates

The lesson from this line of investigation is that drug repurposing can generate useful hypotheses, but a plausible molecular mechanism is only the beginning of the process.

Mefenamic acid has also been the subject of a patent family for autism, “Treatment and prevention of autism and autism spectrum disorders, associated with Knut Wittkowski and ASDERA. The filings cover mefenamic acid and related fenamates, alone or combined with other agents, and describe potassium, chloride and calcium channel modulators. Wittkowski’s published rationale, however, centres mainly on calcium-activated chloride channels (anoctamins), with mefenamic acid’s potassium-channel effects as only part of its pharmacology. ASDERA’s prodrug of mefenamic acid, ASD-002, was licensed to Q BioMed for development in autism with loss of language. A patent shows that an idea has been protected, not that the drug works. There is no mention in the patent that mefenamic acid or its prodrug benefits sound sensitivity.

In some people (Monty and others) a low dose of Ponstan alleviates sound sensitivity almost immediately.

 

5. What about SK, Kv3 and Slack channels?

BK channels are not the only potassium channels that might be relevant to sensory hypersensitivity.

SK channels are another calcium-sensitive potassium-channel family. They help regulate after-hyperpolarisation and the pattern of neuronal firing.

Chlorzoxazone can also affect SK currents, although its effects on these channels are less prominent than its BK-channel effects in the experimental literature. In the 2024 Fragile X mouse study, the investigators found that chlorzoxazone only partially restored impaired SK currents.

This illustrates why it is important not to assume that a drug's behavioural effects arise exclusively from its most prominent molecular target.

Kv3 channels are also relevant to auditory processing. A 2019 study found abnormalities in high-threshold potassium currents in the auditory brainstem of Fragile X mice and investigated Kv3-channel modulators. These experiments suggest that different potassium-channel families may contribute to different aspects of sensory processing.

Read the Kv3 study

That work has continued. Autifony Therapeutics, the company that supplied the Kv3 modulators used in those experiments, lists Fragile X syndrome among the intended uses of its newer Kv3-modulator compounds. A 2026 abstract from a National Fragile X Foundation junior investigator award also reports effects of two Kv3 positive modulators on EEG biomarkers in Fmr1-knockout mice. This is still preclinical, but it is interesting that Kv3 research is now also using EEG measures, the same kind of biomarker approach used in the codabakalner studies.

FRAXA: Potassium channel modulators to treat Fragile X

NFXF 2026 junior investigator awardees

The Yale group behind the Kv3 work, led by Leonard Kaczmarek, also found that loss of FMRP has opposite effects on two different potassium channels: Kv3.1 currents are increased, while Slack currents are decreased. FMRP directly binds the Slack channel and activates it. This is a good illustration of the point made earlier in this post. Within one disorder, one channel may need to be dampened and another boosted, so "potassium-channel activation" is not a single strategy.

The broader point is that sensory hypersensitivity is not necessarily a single biological phenomenon. Different individuals may have different abnormalities in auditory processing, neuronal firing or network synchronisation.

 

6. Where does this leave the channelASD hypothesis?

I would now distinguish three levels of evidence.

First, genetic evidence. Pathogenic variants in several potassium-channel genes can cause neurodevelopmental disorders that include autistic features. This is strong evidence that ion-channel dysfunction can contribute to particular forms of autism. For BK channels, the human evidence is thinner, consisting of isolated cases such as the KCNMA1 disruption reported in 2006, plus the Fragile X link through FMRP.

Second, experimental therapeutic evidence. Studies of chlorzoxazone and other potassium-channel modulators in Fragile X models show that correcting aspects of channel function can improve selected experimental outcomes. Kv3 modulators have shown similar effects on auditory and sensory measures in mice. These findings support further research but do not establish clinical efficacy.

Third, clinical translation. Azetukalner has advanced into regulatory review for epilepsy, with Phase 3 depression studies reporting from 2027. Codabakalner has produced preliminary human EEG and cognitive findings in Fragile X syndrome and is about to be investigated in an EEG-selected autism subgroup, while KER-0193 is following it into Phase 2 in Fragile X.

These developments make the field more promising than it was when I first wrote about channelASD. However, none of these drugs has established efficacy in autism.

The most interesting question is whether we can identify a particular physiological abnormality, establish its mechanism, and then select a drug that corrects that abnormality.


Conclusion

The recent progress in potassium-channel drug development is encouraging. My original interest in channelASD was based on the idea that autism encompasses multiple biological conditions, some of which might be amenable to targeted pharmacological treatment.

Azetukalner shows that Kv7 modulation has reached an advanced stage of clinical development for epilepsy, and its depression trials will show how far the approach extends. Codabakalner is taking BK-channel modulation into a biomarker-enriched autism trial, and KER-0193 gives the BK target a second clinical programme. Earlier work with chlorzoxazone, Kv3 modulators and other compounds provides additional experimental support for investigating potassium channels in Fragile X syndrome and related neurodevelopmental conditions.

The challenge is to move beyond the broad observation that ion channels matter. We need to identify which channel is abnormal, in which individuals, in which direction, and whether correcting it produces a meaningful improvement.

That is the real promise of channelASD: not one treatment for all autism, but the possibility of matching a treatment to a demonstrable biological abnormality.

 



Tuesday, 18 February 2025

Chlorzoxazone for sound sensitivity (hyperacusis) and hyper-excitable neural circuits in Fragile X and broader autism – an alternative to Ponstan? Why is Gallic acid beneficial in Autism? Varenicline and other nicotinic therapies, revisited

  


 

Today’s post covers some practical interventions raised recently either in the research, or in the comments section.

 

·         Chlorzoxazone (via Potassium channels – BKCa, SKCa) an old muscle relaxant first approved in 1958

·         Varenicline a drug approved in 2006 that targets nicotinic receptors in the brain

·         Nicotine

·         Tropisetron, an anti-nausea drug that also targets nicotinic receptors in the brain; it was approved in 1992 in Switzerland and is available in the Europe but not the US.

·         Gallic acid, a component of numerous plants/foods (grapes, pomegranates, green tea, red wine etc) that have been used in traditional medicine across different cultures

 

The common link between the first four is the sensory problems usually found across all severities of autism, and some forms of ADHD/autism-lite. It can be either sound sensitivity (hyperacusis) or misophonia (impaired sensory gating), both of which often co-occur in the same person.

We will refer to some of the excellent research into Fragile X syndrome. This is the most common single gene type of autism; most autism is polygenic and some is not of genetic origin at all (hypoxia during birth, sepsis etc).

 

Let’s start with the easiest topic.

 

Gallic acid

I saw the recent study below and wondered what is gallic acid.

 

Vitamin C and Gallic Acid Ameliorate Motor Dysfunction, Cognitive Deficits, and Brain Oxidative Stress in a Valproic Acid‐Induced Model of Autism

Autism, a developmental‐neurodegenerative disorder, often manifests as social communication difficulties and has been correlated to oxidative stress in the brain. Vitamins C and gallic acid (GA) possess potent antioxidant properties, making them potential candidates for addressing autism‐related issues. This study examined the influence of vitamin C (Vit C) and GA on behavioral, motor, and cognitive performance, along with the assessment of brain oxidative markers, using an experimental model of autism.

Finding

The prenatal VPA‐induced autism model increased nociceptive threshold, heightened anxiety‐like behaviors, impaired balance power, delayed spatial learning, elevated malondialdehyde, and decreased glutathione and catalase levels in the brains of the male offspring. Administration of Vit C and GA effectively mitigated these anomalies.

Conclusions

Vit C and GA could potentially alleviate anxiety‐like behaviors, motor and cognitive deficits, and brain oxidative stress markers in a prenatal rat autism model. This underscores their viability as potential pharmacological interventions for treating autistic dysfunction.

 

Gallic acid is a naturally occurring organic acid widely found in various plants, fruits, and foods. It is notable for its antioxidant, anti-inflammatory, and antimicrobial properties, making it of interest in health and medicine.

For no obvious reason, gallic acid has never been commercialized as a supplement, but gallic acid is one of the reasons a glass of red wine a day may well be good for you.  It can give a you a 20 mg dose of gallic acid.

Red wines made from grape varieties with higher tannin content, such as Cabernet Sauvignon or Pinot Noir, tend to have higher levels of gallic acid because tannins contain gallic acid. Longer aging, especially in oak barrels, can increase gallic acid due to the extraction from the wood.

The new study suggests that gallic acid is a potential pharmacological intervention for treating autism.  It joins an already very long list! 

 

Varenicline and other nicotinic therapies

Our reader Dragos in Romania recently asked for help obtaining Varenicline, which is also sold as Chantix. This drug is similar to using a nicotine patch, but different in some important ways.

DAN doctors in the US used to prescribe nicotine patches to children with autism.

There is a lot of research to support the use  of therapies that target a specific nicotinic receptor in the brain called the alpha 7 nicotinic acetylcholine receptor (α7 nAChR).

Nicotine itself activates all nicotinic receptors, not just α7 nAChR.

Dragos want to trial the smoking cessation drug Varenicline, which targets α7 nAChRs and a little bit the one called α4β2 nAChR.

 

α7 nAChRs

These receptors are well known to be implicated in diseases such as Alzheimer's, schizophrenia, autism, and epilepsy.

They affect:

Cognition and memory

·        α7 nAChRs are involved in synaptic plasticity, learning, and memory formation due to their role in calcium signaling and modulation of neurotransmitter release.

·        Highly expressed in the hippocampus, which is critical for memory processing.

Neuroprotection

·        Calcium influx through α7 nAChRs activates signaling pathways that promote cell survival and neuroprotection.

·        Involved in reducing neuroinflammation and protecting against excitotoxicity.

Modulation of Neurotransmitter Release

·        Regulate the release of dopamine, glutamate, GABA, and serotonin, impacting mood, arousal, and reward mechanisms.

Inflammatory Regulation

·        Present on immune cells, where they regulate the release of pro-inflammatory cytokines like TNF-α via the cholinergic anti-inflammatory pathway.

Sensory Gating

·        α7 nAChRs are crucial for sensory filtering, preventing sensory overload. Dysfunction in these receptors is linked to conditions like autism and schizophrenia.

 

α4β2 nAChRs

These play a role in:

Cognitive function

·        Involved in attention, learning, and memory.

·        Enhances synaptic plasticity in brain regions like the hippocampus.

Dopamine release

Pain modulation

Mood regulation

 

Research has shown reduced expression of both α7 nAChRs and α4β2 nAChRs in the brains of people with autism.

Dragos has good reason to trial Varenicline; not only has another young adult in Romania with severe autism recently responded well, but there are published case reports to give further support.

 

Varenicline in Autism: Theory and Case Report of Clinical and Biochemical Changes

Objective: To explore the potential benefits of varenicline (CHANTIX®), a highly specific partial agonist of neuronal α4β2 nicotinic acetylcholine receptors (nAChR), for autistic symptoms, and present resulting biochemical changes in light of dopamine-related genotype.

Methods: The clinical and biochemical changes exhibited by a 19-year-old severely autistic man following the use of low-dose varenicline in an ABA experiment of nature, and his genotype, were extracted from chart review. Clinical outcome was measured by the Ohio Autism Clinical Impression Scale and 12 relevant urine and saliva metabolites were measured by Neuroscience Laboratory.

Results: With varenicline, this patient improved clinically and autonomic biochemical indicators in saliva and urine normalized, including dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), epinephrine, norepinephrine, taurine, and histamine levels. In addition, with varenicline, the dopamine D1 receptor (DRD1) antibody titer as well as the percent of baseline calmodulin-dependent protein kinase II (CaM KII) activity dropped significantly. When varenicline stopped, he deteriorated; when it was resumed, he again improved. Doses of 0.5, 1, and 2 mg daily were tried before settling on a dose of 1.5 mg daily. He has remained on varenicline for over a year with no noticeable side effects.

Conclusion: This report is, to the best of our knowledge, only the second to demonstrate positive effects of varenicline in autism, the first to show it in a severe case, and the first to show normalization of biochemical parameters related to genotype. As with the previous report, these encouraging results warrant further controlled research before clinical recommendations can be made.

 

Varenicline vs Nicotine 

Let’s compare the mechanisms of action:


Varenicline

  • Partial agonist at the α4β2 nicotinic acetylcholine receptor (nAChR) and a full agonist at α7 nAChRs.
  • Modulates neurotransmitter release (e.g., dopamine, glutamate), which may improve cognitive function and reduce repetitive behaviors in ASD.
  • FDA-approved for smoking cessation.

 

Nicotine Patches

  • Deliver nicotine, a full agonist at nAChRs.
  • Broadly activate multiple nAChR subtypes, leading to enhanced cholinergic signaling.
  • Typically used for smoking cessation

 

Other Considerations

Varenicline

·         Offers more targeted modulation of nAChRs with less widespread cholinergic activation.

  • Varenicline’s mechanism prevents full desensitization, maintaining its effects over time.

·         May be preferred if minimizing side effects like overstimulation is important.

 

Nicotine Patches:

  • Easy to administer and widely available but less specific in its action, which may lead to more off-target effects.
  • Nicotine can lead to rapid receptor desensitization and tolerance, especially with continuous delivery via patches.

 

Alternatives

There are some theoretical alternatives, such as:

 

ABT-126 (Pozanicline)

·         Type: Selective α7 nAChR agonist.

·         Status: Investigated for Alzheimer's disease and schizophrenia.

·         Cognitive enhancement and improved sensory gating.

 

RG3487 (MEM 3454)

·         Type: Partial α7 nAChR agonist and modulator of glutamate receptors.

·         Status: Investigated for schizophrenia and cognitive impairment.

·      Improves cognition and reduces symptoms like sensory gating deficits.

 

The one that caught my attention previously when writing about this subject was Tropisetron.

 

Tropisetron:

  • Already approved as an antiemetic but also acts as a weak α7 nAChR agonist.
  • Potential benefits in cognitive and inflammatory disorders.

 

Clinical Evidence with Tropisetron

Schizophrenia

Early studies show cognitive and sensory gating improvements in schizophrenia patients treated with tropisetron.


One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia


Not to forget Vagus Nerve Stimulation (VNS)

The vagus nerve activates α7 nAChRs on immune cells, reducing inflammation without immunosuppression.

The vagus nerve indirectly affects α7 and α4β2 nAChRs in the brain by modulating acetylcholine release.

Vagus nerve stimulation is already used in epilepsy, depression, and inflammatory disorders.

 

It is worthwhile highlighting the effect on people with some types of GI disorder. There is a known association between Asperger’s and ulcerative colitis.

 

Nicotine and Ulcerative Colitis (UC)


·         Smoking appears to have a protective effect on ulcerative colitis.

·         Smokers are less likely to develop UC, and those who quit smoking are at higher risk of developing the condition.

·         Current smokers with UC may experience milder disease with fewer flares and less severe symptoms.


The suggested mechanism


·         Dysregulated inflammation in the colonic mucosa leads to ulcerations, diarrhea, and abdominal pain.

·         α7 nAChR activation may reduce this inflammation, aiding in mucosal healing and symptom improvement.

·         Nicotine’s anti-inflammatory effects may play a role by modulating cytokine release (e.g., reduced IL-8 and TNF-α).

·         Nicotine also stimulates mucus production and increases colonic blood flow, potentially improving mucosal healing.

·         Smoking-induced changes in the microbiome may also reduce UC severity.

 

Note that for Crohn's Disease (CD) and Irritable Bowel Syndrome (IBS) smoking makes the symptoms worse.

 

So, it would make sense to use vagal nerve stimulation for inflammatory bowel disease?

 

Here are results from 2023

 

Vagus nerve stimulation reduces inflammation in children with inflammatory bowel disease

 

Bioelectronic medicine researchers at The Feinstein Institutes for Medical Research and Cohen Children’s Medical Center published results today, in the journal Bioelectronic Medicine, from a proof-of-concept clinical trial that showed non-invasive, non-pharmacological transcutaneous auricular vagus nerve stimulation (ta-VNS), or stimulating in the ear, significantly reduced inflammation in more than 64 percent of pediatric patients with IBD. 

Dr. Sahn and his team used a commercially available transcutaneous electrical nerve stimulator (TENS) unit (TENS 7000) and sensor probe for the trial. Two earbuds on the probes were placed on a small area of the external ear called the cymba conchae, where the vagus nerve is most accessible. For five-minute intervals, the patients received the stimulation for a total of 16 weeks.




 Finally to BKCa and SKCa channels in Fragile X syndrome (FXS) and broader autism !

 

Let’s have a quick recap on Fragile X.

 

Fragile-X

Fragile X (FXS) is the most common single gene cause of intellectual disability (IQ less than 70).

FXS affects approximately 1 in 4,000 males and 1 in 8,000 females.

The condition is very well studied and the Fragile X gene (FMR1) is considered an autism gene.

I am surprised how rarely (never?) FXS parents comment in this blog. They are actually the ones who stand to benefit the most, given how well-studied their syndrome is and how many treatment options exist. I was recently discussing this exact point with an autism therapist with an FXS patient – why do parents remain passive and not react?

 

More severe in males than females

Males have one copy of the FMR1 gene, while females have two.

In females with the full mutation, symptoms are generally less severe than in males due to what is called random X-inactivation. Since females have two X chromosomes, one of the X chromosomes in each cell is randomly inactivated. In cells where the X with the mutation is inactivated, FMRP is produced normally, and in cells where the normal X is inactivated, no FMRP is produced. The severity of symptoms often correlates with the proportion of cells in which the mutated X is active.

In a strange twist of fate females with the milder form of FXS, called premutation, have the greatest chance of being infertile. This is due to Fragile X-associated primary ovarian insufficiency (FXPOI).

 

Testing

The ability to conduct genetic testing began in the 1990s, became more widespread by the mid-1990s, and became integrated into routine clinical practice in the early 2000s. Today, genetic testing for Fragile X is a standard tool used to diagnose FXS, assess carrier status, and inform genetic counselling.

You can also identify Fragile X based on facial features and this is a common practice, especially in the early diagnosis of individuals with the syndrome.



BKCa and SKCa channels in autism and Fragile X

Ion channel dysfunctions play a key role in all neurological conditions. A great deal is known about them, making them an excellent target for intervention.

Fragile X is such a well-studied condition that you can access all the information very easily.

For other single gene autisms and the more common idiopathic (unknown cause) autism it is more a matter of guesswork. 

This recent paper is excellent: 


Channelopathies in fragile X syndrome


The paper lists all the proven ion channel dysfunctions and suggests how to treat some of them.

Potassium channels – BKCa, SKCa, Kv1.2, Kv3.1, Kv4.2,

Calcium channels – Cav1.3, Cav2.1, Cav2.3,

Misc – HCN, NKCC1, AMPAR, NMDAR, GABAAR

 

Targeting BKCa, SKCa in Fragile X and for hyperacusis in broader autism

In FXS, hyperexcitability in brain circuits is thought to contribute to cognitive and behavioral symptoms.

Preclinical studies suggest that SKCa and BKCa channel activators may correct this hyperexcitability and improve neural network function.

The therapeutic effects of a cheap drug called chlorzoxazone in FXS models are believed to stem from its ability to enhance BKCa channel activity. These channels play a pivotal role in regulating neuronal firing rates and neurotransmitter release. By activating BKCa channels, chlorzoxazone may counteract the neuronal hyperexcitability observed in FXS, leading to improved behavioral and sensory outcomes.

BKCa channels are indispensable for hearing, as they regulate frequency tuning, temporal precision, and signal transmission in both cochlear hair cells and auditory neurons. Dysfunctions in these channels are linked to hearing impairments like frequency discrimination deficits, tinnitus, and hyperacusis (sound sensitivity). Modulating BKCa activity offers a promising avenue for treating auditory disorders.

 

Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome

Fragile X syndrome (FXS) is an X-linked neurodevelopmental disorder characterized by several behavioral abnormalities, including hyperactivity, anxiety, sensory hyper-responsiveness, and autistic-like symptoms such as social deficits. Despite considerable efforts, effective pharmacological treatments are still lacking, prompting the need for exploring the therapeutic value of existing drugs beyond their original approved use. One such repurposed drug is chlorzoxazone which is classified as a large-conductance calcium-dependent potassium (BKCa) channel opener. Reduced BKCa channel functionality has been reported in FXS patients, suggesting that molecules activating these channels could serve as promising treatments for this syndrome. Here, we sought to characterize the therapeutic potential of chlorzoxazone using the Fmr1-KO mouse model of FXS which recapitulates the main phenotypes of FXS, including BKCa channel alterations. Chlorzoxazone, administered either acutely or chronically, rescued hyperactivity and acoustic hyper-responsiveness as well as impaired social interactions exhibited by Fmr1-KO mice. Chlorzoxazone was more efficacious in alleviating these phenotypes than gaboxadol and metformin, two repurposed treatments for FXS that do not target BKCa channels. Systemic administration of chlorzoxazone modulated the neuronal activity-dependent gene c-fos in selected brain areas of Fmr1-KO mice, corrected aberrant hippocampal dendritic spines, and was able to rescue impaired BKCa currents recorded from hippocampal and cortical neurons of these mutants. Collectively, these findings provide further preclinical support for BKCa channels as a valuable therapeutic target for treating FXS and encourage the repurposing of chlorzoxazone for clinical applications in FXS and other related neurodevelopmental diseases.

  

·        Chlorzoxazone

In the FXS research they repurpose a drug called chlorzoxazone to activate BKCa channels, with positive results

 

·        Mefenamic acid (Ponstan)

In this blog Ponstan has shown promise to treat hyperacusis. Ponstan is a known activator of both BKCa and SKCa channels.

 

Which is “better” chlorzoxazone or Ponstan?

According to the science chlorzoxazone is more potent than Ponstan in affecting both BKCa and SKCa channels.

Ponstan has more effects on Kv channels like Kv7. Kv7 is implicated in autism and epilepsy.

In terms of gene expression Ponstan has more direct effects on gene expression due to its modulation of inflammatory pathways and inhibition of prostaglandin synthesis.

Chlorzoxazone primarily acts on ion channels, and its effects on gene expression are secondary and less pronounced.

In conclusion the two drugs are very different, both potentially useful, and some of their actions, such as on hyperacusis, are overlapping.

  

Conclusion

Chlorzoxazone an inexpensive drug used to treat muscle spasms is also known for its effects on calcium-activated potassium channels (BKCa and SKCa).

Some claim that Chlorzoxazone may affect GABAa and/or GABAb receptors, but that appears not to be the case.

The research suggests that Chlorzoxazone should have a beneficial effect in FXS and very likely would have a benefit in some broader autism and in hyperacusis specifically.

The effects of Chlorzoxazone are likely to overlap with the effects of Ponstan. Ponstan is quite possibly also going to be effective in FXS, as it is in broader autism.

There are many suggested therapies for FXS (Metformin, Lovastatin, Baclofen, Acamprosate, Gabapentin, Minocycline, Memantine, Rapamycin, L-carnitine, Omega 3 etc). None, when taken alone, are game-changers.

Every parent of a child with Fragile X should read the paper I have linked to in this post.

 

Channelopathies in fragile X syndrome

 

It is full of excellent ideas. If NKCC1 is overexpressed, as is suggested, trial bumetanide.

As in all autism, polytherapy is going to be key. No single therapy can be highly effective with so many dysfunctions present. To quote from the above paper:-

 “Ultimately, the most effective treatment strategies are likely to be multifactorial.”

This means do not be surprised if you need 5 different drugs, with 5 different targets to produce a game-changing effect. Better 5 cheap old re-purposed generic drugs than a single brand-new drug with little overall effect and that costs a king’s ransom, each and every year.

Unfortunately, a personalized approach will need to be used to find such a polytherapy. What works at one age may not be beneficial at another age. Even within single gene autisms, treatment response can vary widely from person to person.

At a conference, I did ask a clinician who is an “expert” in Fragile X, does she apply any of the existing therapies from the research, to her patients. She was rather taken aback by the idea and said “no, we have to follow the protocols.” So, an expert in exactly what then? An expert would make the protocols, if none existed.